RE:RE:RE:RE:RE:RE:Is anyone one adding? Why or why not?I read all the complaints about management and the board and I understand the frustration with the company's performance, but I don't understand the idea to vote out the whole board, or even a single member of the board since there is no way to evaluate each member's contribution. I am old enough on this board to remember the reaction of some when Thera bought Katana. It was seen as just a lottery ticket, and now, just three years later, it is the main program of the company. Katana was bought under the former CEO, Luc Tanguay who was seen as an incompetent by some here. The same who are explaining to us the potential of the cancer market and how the company should be run...
Personnally, I am frustrated by only one thing, and it is the very poor guidance the company gave on the timeline to complete phase Ia. You cannot be so wrong about something like that. It raises questions about the understanding of the clinical trial realities by the company and it sows doubt about things to come. They did the same with the NASH program. The were too optimistic and had to find a way to walk back their promises. Overpromising and underdelivering lead to what we see with the stock price. The level of confidence in the potential of the company is low because they underdeliver and need to walk back on their plans, NASH, Trogarzo in Europe, and huge delay in phase Ia in oncology. That does not mean that it will all end up in nothing of value, but at this point, it is only negative news, delays, and postponements.